NASDAQ: KNSAKiniksa Pharmaceuticals Ltd Stock
$20.19-0.07 (-0.35%)
Updated May 9, 2024
KNSA Price
$20.19
Fair Value Price
$35.95
Market Cap
$1.43B
52 Week Low
$13.02
52 Week High
$22.09
P/E
168.25x
P/B
3.32x
P/S
4.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$301.77M
Earnings
$8.65M
Gross Margin
87.8%
Operating Margin
-7.15%
Profit Margin
2.9%
Debt to Equity
0.2
Operating Cash Flow
$22M
Beta
0.94
Next Earnings
Jun 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A
KNSA Overview
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KNSA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KNSA ($20.19) is undervalued by 43.84% relative to our estimate of its Fair Value price of $35.95 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KNSA ($20.19) is significantly undervalued by 43.84% relative to our estimate of its Fair Value price of $35.95 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
KNSA was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KNSA due diligence checks available for Premium users.
Be the first to know about important KNSA news, forecast changes, insider trades & much more!
KNSA News
Valuation
KNSA fair value
Fair Value of KNSA stock based on Discounted Cash Flow (DCF)
Price
$20.19
Fair Value
$35.95
Undervalued by
43.84%
KNSA ($20.19) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KNSA ($20.19) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KNSA was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KNSA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
168.25x
Industry
5.22x
Market
29.92x
KNSA is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
KNSA is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
KNSA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.32x
Industry
5.97x
KNSA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KNSA's financial health
Profit margin
Revenue
$79.9M
Net Income
-$17.7M
Profit Margin
-22.2%
KNSA's Earnings (EBIT) of -$21.56M... subscribe to Premium to read more.
Interest Coverage Financials
KNSA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$519.7M
Liabilities
$87.8M
Debt to equity
0.2
KNSA's short-term assets ($270.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KNSA's short-term assets ($270.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KNSA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KNSA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$4.0M
Investing
$25.5M
Financing
$3.6M
KNSA's operating cash flow ($21.56M)... subscribe to Premium to read more.
Debt Coverage Financials
KNSA vs Biotech Stocks
Kiniksa Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.